Theravance Biopharma (TBPH) News Today $9.31 -0.35 (-3.62%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.31 0.00 (0.00%) As of 02/21/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Theravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 20 at 6:00 AM | prnewswire.comTheravance Biopharma (TBPH) Projected to Post Quarterly Earnings on MondayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Monday, February 24. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665706)February 17, 2025 | marketbeat.comTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025February 12, 2025 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 5, 2025 | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 52-Week High - Here's WhyTheravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's WhyJanuary 25, 2025 | marketbeat.comTheravance Biopharma stock hits 52-week high at $10.47January 24, 2025 | msn.comTheravance Biopharma (NASDAQ:TBPH) Shares Up 8.8% - Still a Buy?Theravance Biopharma (NASDAQ:TBPH) Trading Up 8.8% - Time to Buy?January 24, 2025 | marketbeat.comTheravance biopharma SVP Rhonda Farnum sells $36,000 in sharesJanuary 24, 2025 | msn.comRhonda Farnum Sells 4,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) StockJanuary 24, 2025 | insidertrades.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 SharesTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 309,565 shares of the company's stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 23, 2025 | marketbeat.comBarclays PLC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Barclays PLC grew its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 279.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,580 shares of the biopharmaceutical company's stock aJanuary 18, 2025 | marketbeat.comZacks Research Issues Positive Forecast for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research lifted their Q2 2026 earnings estimates for Theravance Biopharma in a report released on Monday, January 13th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will poJanuary 16, 2025 | marketbeat.comAnalysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)January 7, 2025 | uk.finance.yahoo.comState Street Corp Decreases Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)State Street Corp lowered its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 6.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,191,621 shares of the biopharmaceutical company's stock after selling 75,754 shares during the quartDecember 27, 2024 | marketbeat.comWellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Wellington Management Group LLP lessened its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 45.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 191,329 shares of the biopharmaceutical comDecember 19, 2024 | marketbeat.comTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferenceDecember 17, 2024 | prnewswire.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from AnalystsTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has been given an average recommendation of "Hold" by the five brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued aDecember 9, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 143,781 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)BNP Paribas Financial Markets raised its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 88.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 305,480 shares of the biopharmaceutical company's stockDecember 7, 2024 | marketbeat.comZacks Research Issues Pessimistic Outlook for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities researchers at Zacks Research dropped their FY2024 earnings per share (EPS) estimates for shares of Theravance Biopharma in a research report issued to clients and investors on Tuesday, December 3rd. Zacks Research analyst R. DeparDecember 6, 2024 | marketbeat.comAlgert Global LLC Invests $851,000 in Theravance Biopharma, Inc. (NASDAQ:TBPH)Algert Global LLC bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 105,609 shares of the biopharmaceutical company's stock, valued at approximately $851,000. Algert Global LLC ownNovember 30, 2024 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceNovember 20, 2024 | prnewswire.comTheravance Biopharma’s Third Quarter 2024 Financial InsightsNovember 14, 2024 | markets.businessinsider.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from AnalystsShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have issued aNovember 14, 2024 | marketbeat.comTheravance Biopharma (TBPH) Receives a Hold from Evercore ISINovember 14, 2024 | markets.businessinsider.comTheravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...November 13, 2024 | uk.finance.yahoo.comBalanced View on Theravance Biopharma: Strong Growth Amidst Financial Challenges and Strategic UncertaintyNovember 13, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Theravance Biopharma Amid Positive Momentum and Strategic InitiativesNovember 13, 2024 | markets.businessinsider.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above 50-Day Moving Average - What's Next?November 13, 2024 | marketbeat.comTheravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comTheravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder ValueNovember 12, 2024 | prnewswire.comWhat To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 EarningsNovember 11, 2024 | finance.yahoo.comTheravance Biopharma (TBPH) Scheduled to Post Earnings on TuesdayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639930)November 5, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lowered its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 90.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,853 shares of the biopharmOctober 26, 2024 | marketbeat.comTheravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024October 24, 2024 | prnewswire.comWhat is Zacks Research's Forecast for TBPH Q3 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now anticipates tOctober 23, 2024 | marketbeat.comWhat is Zacks Research's Estimate for TBPH Q4 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Zacks Research upped their Q4 2025 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now forecasts that tOctober 22, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by AnalystsTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has earned a consensus rating of "Hold" from the five analysts that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommeOctober 20, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What HappenedTheravance Biopharma (NASDAQ:TBPH) Share Price Crosses Below 200 Day Moving Average - Time to Sell?October 19, 2024 | marketbeat.comTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseaseOctober 18, 2024 | prnewswire.comDimensional Fund Advisors LP Purchases 91,679 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Dimensional Fund Advisors LP raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 38.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,181 shares of the biopharmaceuticalOctober 11, 2024 | marketbeat.comSquarepoint Ops LLC Makes New $986,000 Investment in Theravance Biopharma, Inc. (NASDAQ:TBPH)Squarepoint Ops LLC bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 116,256 shares of the biopharmaceutical company's stock, valued at approximately $986,000. Squarepoint OpOctober 7, 2024 | marketbeat.comBank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Bank of Montreal Can lifted its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 141.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 160,138 shares of the biopharmaceutical company's stock afOctober 6, 2024 | marketbeat.comMarshall Wace LLP Grows Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Marshall Wace LLP boosted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 83.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 297,499 shares of the biopharmaceutical company's stock afOctober 4, 2024 | marketbeat.comInvest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He DumpedSeptember 29, 2024 | 247wallst.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from BrokeragesShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and two have given a buySeptember 25, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Stake Lessened by Baupost Group LLC MABaupost Group LLC MA decreased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 36.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,200,021September 21, 2024 | marketbeat.comBuy Rating Affirmed for Theravance Biopharma on Yupelri Growth and Ampreloxetine Pipeline ProgressSeptember 16, 2024 | markets.businessinsider.comTheravance Biopharma (NASDAQ:TBPH) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Monday.September 16, 2024 | marketbeat.comSeth Klarman's Complete Exit from Theravance Biopharma IncSeptember 11, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn SituationSeptember 6, 2024 | finance.yahoo.com Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Media Mentions By Week TBPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼0.000.60▲Average Medical News Sentiment TBPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼22▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NAMS News IDYA News SDGR News TVTX News BLTE News VERA News PRAX News DVAX News GLPG News WVE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
